US stock · Healthcare sector · Biotechnology
Company Logo

Idera Pharmaceuticals, Inc.

IDRANASDAQ

0.38

USD
-0.02
(-5.00%)
Market Closed
-0.92P/E
-1Forward P/E
-0.05P/E to S&P500
20.164MMarket CAP
- -Div Yield

Idera Pharmaceuticals, Inc.

NASDAQ:IDRA

RECENT
PRICE

0.38

P/E
RATIO

-0.92

(PEG:- -)

P/E RATIO
RELATIVE
TO S&P

-0.05

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.39 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 09/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

1.17

(7.95)

1.21

- -

3.01

(4.98)

(6.56)

- -

9.31

0.53

8.18

- -

11.79

2.58

(5.37)

- -

5.13

(5.72)

(6.25)

- -

0.02

(6.89)

(5.56)

- -

0.01

(5.57)

(5.76)

0.17

0.01

(3.32)

(3.12)

0.19

0.01

(3.73)

(3.13)

0.08

0.02

(3.38)

(3.04)

- -

1.02

(2.41)

(1.79)

- -

0.05

(3.35)

(2.82)

- -

0.02

(2.25)

(1.95)

- -

0.05

(1.98)

(1.56)

- -

- -

(3.33)

(1.00)

- -

- -

2.90

(0.73)

- -

- -

(0.42)

(0.38)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.04

5.89

0.62

2.91

0.14

7.83

0.04

11.31

0.03

10.53

0.01

3.48

- -

1.92

0.00

5.91

0.11

4.19

0.05

5.81

0.03

6.48

0.01

5.47

0.00

2.41

0.00

(0.39)

0.00

(2.70)

- -

0.87

- -

0.60

CAPEX per share

Book Value per share

2

3

3

3

3

3

3

5

10

14

16

20

27

29

34

34

52

Comm.Shares outs.(m)

(4.3)

(0.2)

- -

(14.2)

(0.8)

- -

174.0

8.1

- -

19.9

0.3

- -

(5.8)

(0.3)

- -

(2.5)

(0.2)

- -

(1.7)

(0.1)

1.8%

(3.3)

(0.2)

1.8%

(7.4)

(0.4)

0.3%

(8.7)

(0.4)

- -

(6.2)

(0.3)

- -

(4.7)

(0.2)

- -

(5.0)

(0.2)

- -

(1.4)

(0.1)

- -

(0.7)

(0.0)

- -

0.7

0.0

- -

(0.9)

(0.0)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$4 m.

Total assets
$30 m.

Long-term debt
$0 m.

Cash and equiv.
$28 m.

Goodwill - -

Retained earnings $(740) m.

Common stock 53 m. shares

Market Capitalisation
$20 m. (as of 25/9/22)

0

(48,783.0)%

0

(39,021.6)%

0

(38,657.4)%

0

(53,084.9)%

0

(19,616.9)%

16

(239.3)%

1

(7,368.8)%

1

(9,207.9)%

1

(3,181.4)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

Revenue (m)

Operating margin

0

(24)

0

(19)

0

(18)

0

(39)

0

(49)

1

(38)

1

(66)

0

(60)

0

(57)

0

(113)

0

98

0

(22)

Depreciation (m)

Net profit (m)

- -

(44,860.4)%

- -

(37,725.5)%

- -

(38,778.7)%

- -

(52,934.2)%

- -

(19,500.0)%

- -

(237.0)%

- -

(7,315.3)%

- -

(9,045.5)%

- -

(3,903.0)%

- -

(Infinity)%

- -

Infinity%

- -

(Infinity)%

Income tax rate

Net profit margin

19

- -

12

6

- -

7

26

- -

32

35

1

43

56

1

84

102

0

103

107

- -

108

64

- -

64

(8)

- -

(11)

34

- -

(91)

29

1

29

26

0

26

Working capital (m)

Long-term debt (m)

Equity (m)

(121.9)%

(92.9)%

(197.7)%

(287.5)%

(177.8)%

(290.3)%

(56.2)%

(49.4)%

(56.2)%

(87.1)%

(75.1)%

(89.0)%

(56.7)%

(52.5)%

(58.1)%

(36.9)%

(33.8)%

(37.1)%

(60.9)%

(55.7)%

(61.3)%

(93.5)%

(82.0)%

(93.6)%

804.1%

(119.0)%

506.0%

(103.7)%

(86.5)%

123.6%

(92.2)%

(79.4)%

333.0%

(77.8)%

(68.0)%

(84.5)%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

43

36

35

Receivables

- -

- -

- -

Inventory

- -

- -

- -

Other

3

4

1

Current assets

46

41

34

Acc. Payable

0

0

1

Debt due

0

0

0

Other

54

7

4

Current liab.

55

7

5

100.0%

- -

103.0%

- -

105.8%

- -

102.1%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

0.6%

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

Idera Pharmaceuticals, Inc. (US) started trading on January 4, 1996 (cik: 0000861838), operates in the Healthcare sector (Biotechnology industry), has 13 full-time employees, and is led by Mr. Vincent Milano. Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

- -

- -

Cash flow

-17.99%

10.82%

Earnings

-25.65%

8.97%

Dividends

- -

- -

Book value

106.51%

107.77%

Insider trading

Type

Shares

Date

Soland Daniel B

Award

66,500

07/06/22

Lim Bryant David

Award

66,500

07/06/22

Kirby John J.

Award

66,500

07/06/22

Milano Vincent

Award

124,000

07/06/22

Dougherty Michael R

Award

50,086

07/01/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.26

(0.72)

(0.61)

(2.27)

-3.33

2021

3.42

(0.22)

(0.18)

(0.12)

2.90

2022

(0.08)

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -